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AbstrAct:
Photoreceptor cell death is the terminal event in a variety of retinal disorders including 
age-related macular degeneration, retinitis pigmentosa, and retinal detachment. 
Apoptosis has been thought to be the major form of cell death in these diseases, however 
accumulating evidence suggests that another pathway, programmed necrosis is also 
important. Recent studies have shown that, when caspase pathways are blocked, 
receptor interacting protein (RIP) kinases promote necrosis and overcome apoptosis 
inhibition. Therefore, targeting of both caspase and RIP kinase pathways are required 
for effective photoreceptor protection. Here, we summarize the current knowledge of 
RIP kinase-mediated necrotic signaling and its contribution to photoreceptor death. 
IntroductIon
Photoreceptor death is the ultimate cause of vision 
loss in many retinal disorders. Photoreceptors die when 
they are physically separated from the underlying retinal 
pigment epithelium (RPE) and choroidal vessels, which 
provide metabolic support to the outer layers of the retina. 
Retinal detachment occurs in various retinal disorders, 
including age-related macular degeneration (AMD) [1], 
diabetic retinopathy [2], as well as rhegmatogenous 
retinal detachment. Although surgery is carried out 
to  reattach  the  retina,  only  two-fifths  of  patients  with 
rhegmatogenous retinal detachment involving the macula 
recover 20/40 or better vision. Histological examination 
of the retina in experimental retinal detachment, which 
is created by subretinal injection of sodium hyaluronate 
in animal eyes, showed that photoreceptor death is first 
identified  at  12  hours,  peaked  by  around  3  days,  and 
dropped to a low level by 7 days after retinal detachment 
(Fig. 1A and B) [3,4,5]. Interestingly, the retina in patients 
with rhegmatogenous retinal detachment exhibits a 
similar pattern and time course of photoreceptor death 
observed in experimental retinal detachment [6]. These 
studies suggest that photoreceptor death may be one of 
the causes of vision loss after retinal detachment. 
AMD is the most common cause of adult blindness 
in the western world [7]. Severe vision loss in late stage 
AMD results from choroidal neovascularization (called 
wet or neovascular AMD) or geographic atrophy (called 
dry  AMD)  [8].  In  wet  AMD,  choroidal  neovascular 
vessels  leak  serous  or  hemorrhagic  fluid,  causing 
detachment of RPE or photoreceptors, subretinal or 
intraretinal  hemorrhage,  and  consequent  fibrovascular 
scarring. Although anti-vascular endothelial growth 
factor (VEGF) therapies have shown visual improvement 
in many patients with neovascular AMD [9,10,11], some 
patients still do not respond to these therapies and 2/3 
of patients do not have visual improvement. Because 
photoreceptor loss underlies the pathology of AMD [12], 
neuroprotective agents targeting photoreceptor death 
may be used in combination with anti-VEGF therapies 
to  improve  visual  outcomes.  In  dry AMD,  geographic 
atrophy is a serious cause of vision loss. It results from 
a slowly progressive atrophy of RPE and photoreceptors. 
Histological studies of geographic atrophy have suggested 
that  RPE  cells  die  first,  followed  by  degeneration  of 
photoreceptors  [1,13].  On  the  other  hand,  macular 
translocation studies have shown that RPE atrophy recurs 
under the translocated macula after surgery, suggesting 
the possibility that photoreceptors may cause RPE 
degeneration in geographic atrophy or that RPE cells are 
impaired in handling the metabolic/trophic demands of 
the macular photoreceptors. [14,15,16]. 
In  other  retinal  degenerative  disorders  such  as 
retinitis pigmentosa, photoreceptor death is the basis 
for visual decline [17]. Retinitis pigmentosa is a group Oncotarget 2011; 2:  497 - 509 498 www.impactjournals.com/oncotarget
of inherited retinal disorders, affecting over 1 million 
individuals worldwide. Although genetic analyses have 
identified  over  40  different  genetic  mutations  [Retinal 
Information Network (RetNet) at http://www.sph.uth.tmc.
edu/Retnet/], the mechanisms by which these mutations 
cause photoreceptor death are unclear and these diseases 
remain intractable [18,19]. Therefore, identification of the 
mechanisms involved in photoreceptor death is critical 
to developing new treatment strategies for these retinal 
disorders associated with photoreceptor loss.
two dIstInct Forms oF cell 
deAth: ApoptosIs And necrosIs 
Apoptosis and necrosis are two distinct modes of cell 
death defined by morphological appearance [20]. In 1972, 
Kerr, Wyllie and Currie used the Greek term ‘apoptosis’ 
(dropping off of petals from plants) to describe a specific 
morphological aspect of cell death [21]. Apoptosis is 
accompanied by rounding-up of the cell, reduction of 
cellular volume, chromatin condensation, and engulfment 
by resident phagocyte. Apoptosis is the best-characterized 
type of programmed cell death, and these morphological 
changes are largely mediated by the activation of caspase 
family of cysteine proteases [22]. In contrast, ‘necrosis’ 
(from the Greek, dead) is associated with a gain in cell 
volume, swelling of organelles, plasma membrane rupture 
and subsequent release of intracellular contents with 
ensuing  inflammation.  Previously,  necrosis  has  been 
considered a passive, unregulated form of cell death, 
but recent evidence indicates that some necrosis can be 
induced by regulated signal transduction pathways such 
as those mediated by RIP kinases [23]. This programmed 
form of necrosis is termed programmed necrosis or 
necroptosis [24,25]. 
methods to detect ApoptosIs And 
necrosIs 
Although several biochemical methods to detect 
cell death have been developed, there is no perfect 
method  that  can  specifically  discriminate  between 
apoptosis and necrosis. For example, whereas detection 
of  phosphatidylserine  exposure  is  known  as  a  marker 
of early apoptosis, necrotic cells also externalize 
phosphatidylserine before membrane permeabilization 
in some cells [26]. TUNEL staining, which was initially 
thought to detect specifically apoptotic cells, also labels 
DNA  breaks  in  necrotic cells [27,28].  Conversely,  cell 
impermeable dye such as propidium iodide, which is used 
to label necrotic cells, also detects late-stage apoptosis. 
Biochemical  detection  of  key  molecular  events  in 
apoptosis (e.g. caspase cleavage) and necrosis (e.g. RIP 
kinase phosphorylation) or inhibition of these molecules 
by pharmacological or genetic approaches may provide 
significant  information  for  the  specific  roles  of  each 
cell death mode. However, it should be noted that these 
molecular pathways are not completely independent and 
may cross-talk with each other especially in the late phase 
of cell death. Although transmission electron microscopy 
has been used less frequently over the past decade, it is 
still one of the most sensitive and direct methods to detect 
morphological changes in cell death [29,30]. Given all of 
these findings, it is apparent that a combination of several 
distinct techniques is needed for the proper classification 
of cell death modalities.
cAspAse sIgnAlIng
Cystein aspartate-specific proteases or caspases are 
the central molecules involved in initiation and execution 
of apoptosis [22]. There are at least 7 mammalian caspases 
that have an important role in apoptosis, and they are 
divided into two major classes: the initiator caspases, 
caspase-2, -8, -9 and -10; and the effector caspases, 
caspase-3, -6, and -7. The initiator caspases cleave inactive 
forms of effector caspases, thereby activating them. Once 
activated, the effector caspases cleave a broad spectrum 
of protein substrates, which in turn lead to induction of 
apoptosis.
Caspase activation occurs mainly through the 
extrinsic  and  intrinsic  pathways  [31]  (Fig.  2).  The 
extrinsic pathway is initiated by binding of extracellular 
death  ligands  such  as  TNF-α  and  Fas  ligand  to  their 
cell-surface  death  receptors  like  TNFR  and  Fas  [32]. 
The death domains of these receptors recruit adaptor 
molecules like Fas-associated death domain (FADD) and 
caspase-8, forming the death inducing signaling complex 
(DISC) [33]. The formation of DISC leads to activation 
of caspase-8, which in turn mediates cleavage of effector 
caspases. The extrinsic pathway can cross-talk with the 
intrinsic pathway through caspase-8-mediated cleavage 
Figure 1: experimental retinal detachment.
A.  Scheme of experimental retinal detachment. Subretinal 
injection of sodium hyaluronate causes physical separation of 
photoreceptors from the underlying RPE.
b. TUNEL staining 3 days after experimental retinal detachment. 
TUNEL  positive  cells  are  detected  in  the  outer  nuclear  layer 
(ONL). INL: inner nuclear layer; GCL: ganglion cell layer; scale, 
50 µm. 
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of Bid, a BH3-only member of the Bcl-2 family proteins 
[34,35]. Bid cleavage releases a truncated fragment that 
triggers the release of mitochondrial proteins, thereby 
initiating intrinsic caspase cascade as described below. 
The intrinsic pathway is mediated by mitochondria 
[36]. In response to intracellular and environmental stress, 
mitochondria release intermembrane proteins such as 
cytochrome c and second mitochondria-derived activator 
of caspases (Smac)/direct inhibitor of apoptosis-binding 
protein with low pI (Diablo) into the cytosol. Released 
cytochrome c triggers the formation of an apoptosome 
along with apoptotic protease activating factor-1 (Apaf-
1) and caspase-9 in the presence of ATP, which leads to 
caspase-9 activation [37]. Smac/Diablo enhances caspase 
activation through the neutralization of inhibitor of 
apoptosis (IAP) proteins [38,39]. 
the role oF cAspAses In 
photoreceptor deAth
There is no doubt that caspases play a central role in 
the induction of apoptosis especially in the early stages; 
however, accumulating evidence suggests that the caspase 
pathway may not be the sole mediator of neuronal cell 
death in pathological conditions. In experimental models 
of retinal detachment, although enzymatic activities of 
caspase-8, -9, -3, and -7 increase in the retina after retinal 
detachment [5,40], caspase inhibition by a pan-caspase 
inhibitor fails to prevent photoreceptor loss [4]. Reduced 
expression of Apaf-1 in forebrain overgrowth mutant 
mice exhibits partial, but not complete, protection against 
photoreceptor death after retinal detachment [41]. There is 
conflicting evidence regarding caspase activation during 
photoreceptor death in inherited retinal degeneration.  Figure 2
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Figure 2: schematic of caspase signaling pathway. The extrinsic pathway is initiated by biding of death ligands such as TNF-α 
and Fas ligand to their cell-surface death receptors such as TNFR and Fas. The death domains of these receptors recruit adaptor molecules 
like FADD and caspase-8, which leads to the activation of caspase-8. Activated caspase-8 cleaves the effector caspases such as caspase-3, 
thereby activating them and inducing apoptosis. The extrinsic pathway interacts with the intrinsic pathway via caspse-8-mediated cleavage 
of Bid. The intrinsic pathway is initiated by release of mitochondrial intermembrane proteins such as cytochrome c and Smac/Diablo into 
the cytosol. Released cytochrome c forms an apoptosome with Apaf-1 and caspase-9, which leads to caspase-9 activation. Smac/Diablo 
enhances caspase activation through the neutralization of IAP proteins. Oncotarget 2011; 2:  497 - 509 500 www.impactjournals.com/oncotarget
Whereas several studies reported an increased activity 
of  caspase-3  and  -8  in  a  model  of  inherited  retinal 
degeneration (rd1 mice), others showed that activation 
of caspase-9, -8, -7, -3, and -2 is not observed in rd1 
mice [42] and that caspase inhibition by the pan-caspase 
inhibitor Z-VAD or testing in mice deficient in caspase-3 
is  not  sufficient  to  prevent  photoreceptor  loss  [43,44]. 
Intraperitoneal injection of a caspase-3 inhibitor provides 
mild and transient protection with no effect after 13 days 
of age in rd1 mice [45]. 
In  the  mature  brain  and  retina,  it  has  been 
demonstrated that caspase-dependent apoptosis is down-
regulated because of a differentiation-associated reduction 
in Apaf-1 and caspase-3 expression and increased efficacy 
of IAPs [46,47,48]. Segura and others reported that the 
long form of the Fas apoptotic inhibitory molecule 
is predominantly expressed in neurons and prevents 
the activation of caspase-8 induced by Fas [49]. Gene 
expression profiling of the retina after retinal detachment 
and in inherited retinal degeneration revealed changes in 
multiple cell death pathways as well as caspase signaling 
[50,51]. Recent studies have shown that several caspase-
independent inducers of cell death such as apoptosis-
inducing  factor  (AIF),  calpains,  and  poly(ADP-ribose) 
polymerases 1 (PARP-1) are activated during retinal 
degeneration  [44,52,53].  These  findings  indicate  the 
involvement of multiple death signaling mechanisms in 
photoreceptor death, and suggest that inhibition of the 
caspase pathway alone may not be sufficient to prevent 
photoreceptor loss in retinal degenerative disorders. 
clInIcAl studIes usIng cAspAse 
InhIbItors
There are only a few clinical trials employing 
Figure 3
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Figure 3: schematic of rIp signaling pathway.
A. In response to TNF-α stimulation, RIP1 is recruited to TNFR and forms a membrane associated complex I with TRADD, TRAF2/5 and 
cIAP1/2, which in turn leads to polyubiquitination of RIP1 and pro-survival NF-κB activation. 
b. RIP1 switches function to a regulator of cell death when RIP1 is unubiquitinated by A20 or CYLD. Deubiquitination of RIP1 leads to 
the formation of cytosolic DISC with FADD and caspase-8, the so-called complex II. In contrast to TNF signaling, Fas stimulation directly 
forms DISC. Activation of caspase-8 in DISC leads to apoptosis induction. During apoptosis, RIP1 is cleaved and inactivated by caspase-8. 
c. In conditions where caspases are blocked or cannot be activated efficiently, RIP1 binds to RIP3, and both RIP1 and RIP3 kinases are 
phosphorylated at RIP1-RIP3 complex. RIP1 kinase phosphorylation is critical for necrosis induction. In response to TNF-α, RIP1 binds 
to NADPH oxidase 1 and produces superoxide. Activated RIP3 binds to PYGL, GLUL and GLUD1 and increases the production of 
mitochondrial ROS. ROS overproduction leads to mitochondrial dysfunction, resulting in the release of mitochondrial pro-death proteins. Oncotarget 2011; 2:  497 - 509 501 www.impactjournals.com/oncotarget
caspase inhibitors in human diseases (http://clinicaltrials.
gov/).  PF-03491390  (formally  called  IDN-6556)  is  an 
anti-apoptotic caspase inhibitor that has advanced into 
phase 2 clinical trials [54]. PF-03491390 is an irreversible 
and  broad-spectrum  caspase  inhibitor,  and  blocks  the 
activities of caspase-1, -2, -3, -6, -7, -8, and -9 [55]. In 
phase 1 and 2 studies, intravenous or oral administration 
of PF-03491390 was generally well tolerated [56,57,58]. 
Oral administration of PF-03491390 significantly reduced 
serum AST and ALT in a phase 2 study for patients with 
chronic hepatitis C virus [57]. Larger clinical studies are 
needed  to  establish  the  safety  and  efficacy  of  caspase 
inhibitors. There has been no caspase inhibitor-based 
clinical study for retinal and neurodegenerative disorders 
[59].
evIdence oF necrosIs In 
photoreceptor loss
Although most of studies have focused on apoptosis 
as a mechanism of photoreceptor death, previous 
morphological analyses demonstrated the presence of 
photoreceptor necrosis as well as apoptosis after retinal 
detachment and retinal photic injury [60,61]. Interestingly, 
Arimura and others showed that the vitreous level of high-
mobility group box 1 (HMGB1) is increased in human 
eyes with retinal detachment [62]. HMGB1 is a nuclear 
DNA-binding  protein,  which  is  mainly  present  in  the 
nucleus and is passively released into the extracellular 
space from necrotic cells [63]. These findings suggest that 
necrosis and subsequent release of intracellular content 
may occur in human retinal degeneration. Furthermore, 
using experimental models of retinal detachment, we 
recently demonstrated via electron microscopy and 
molecular biology analysis that programmed necrosis is 
a significant mode of photoreceptor cell death after RD 
and that the RIP kinase pathway plays an important role in 
the induction of photoreceptor necrosis, especially when 
caspase pathways are inhibited [64]. Rosenbaum and 
others also reported that RIP kinase inhibition by RIP1 
kinase  inhibitor  protects  retinal  neuronal  cells  against 
retinal  ischemic-reperfusion  injury  [65].  Thus,  these 
results suggest that not only apoptosis but also necrosis 
are important for cell death during retinal degeneration, 
and that targeting necrosis signaling may be a novel 
therapeutic strategy for treatment of retinal disorders.
rIp KInAse sIgnAlIng 
rIp1 polyubiquitination mediates pro-survival 
NF-κB activation
RIP1  is  an  adaptor  protein  that  acts  downstream 
of death domain receptors and is essential for both cell 
survival and death [66]. RIP1 consists of an N-terminal 
serine/threonine kinase domain, an intermediate domain, 
a  RIP  homotypic  interaction  motif  (RHIM),  and  a 
C-terminal  death  domain.  After  TNF-α  stimulation, 
RIP1  is  recruited  to  TNFR  and  forms  a  membrane 
associated complex I with TNF receptor-associate death 
domain (TRADD), TNF receptor-associated factor 2 or 
5 (TRAF2/5) and cellular IAP1 or 2 (cIAP1/2), which 
in  turn  leads  to  polyubiquitination  of  RIP1  [67,68]. 
This polyubiquitin chain serves as an assembly site for 
transforming growth factor-β-activated kinase-1 (TAK1), 
TAK1 binding protein 2 or 3 (TAB2/3) and inhibitor κB 
kinase (IKK) complex, and mediates pro-survival NF-κB 
activation (Fig. 3A)[69]. Cells deficient for both cIAP1 
and cIAP2, in which RIP1 polyubiquitination and NF-κB 
activation  are  blunted,  are  sensitized  to  TNF-mediated 
cell  death  [68,70].  Consistent  with  these  results,  RIP1 
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Figure 4: caspase inhibition exacerbates necrosis after 
retinal detachment. 
A-c. TEM photomicrographs of photoreceptors 3 days after 
retinal detachment in the retina treated with vehicle (A), pan-
capase inhibitor Z-VAD (B), or Nec-1+Z-VAD (C). A: apoptotic 
cell. N: Necrotic cell. Scale bar, 5 µm. Photoreceptors showing 
cellular  shrinkage  and  nuclear  condensation  were  defined  as 
apoptotic cells, while photoreceptors associated with cellular 
and organelle swelling and discontinuities in plasma and nuclear 
membrane  were  defined  as  necrotic  cells.  Electron-dense 
granular materials were labeled simply as end-stage cell death/
unclassified.
d.  Quantification  of  apoptotic  and  necrotic  photoreceptor 
death after retinal detachment. Z-VAD treatment decreased 
apoptosis but exacerbates necrosis. Nec-1+Z-VAD significantly 
suppressed necrotic photoreceptor death. Oncotarget 2011; 2:  497 - 509 502 www.impactjournals.com/oncotarget
knockout  mice  die  soon  after  birth  with  reduced  NF-
κB activation and extensive apoptosis in lymphoid and 
adipose tissues [71]. 
rIp1 kinase phosphorylation at the crossroad of 
apoptosis and necrosis
RIP1 switches its function to a regulator of cell death 
when it is deubiquitinated by A20 or cylindromatosis 
(CYLD) [72,73]. Deubiquitination of RIP1 abolishes its 
ability to activate NF-κB after TNF-α stimulation, and 
leads to the formation of cytosolic DISC with FADD and 
caspase-8,  the  so-called  complex  II  [67]. As  described 
above in caspase signaling,  DISC  formation  leads  to 
caspase-8 activation and subsequent apoptosis. In contrast 
to TNF signaling, Fas directly recruits RIP1, FADD and 
caspase-8 to the plasma membrane and forms DISC (Fig. 
3B) [74,75,76]. During apoptosis, RIP1 is cleaved and 
inactivated by caspases [77]. 
Although many cell lines are protected against death 
receptor-induced apoptosis by a pan-caspase inhibitor, 
Vercammen  and  others  found  that,  in  mouse  L929 
fibrosarcoma cells, caspase inhibition does not prevent 
TNF- or Fas-induced cell death and the cells acquire a 
necrotic morphology [78,79]. In 2000, Holler and others 
discovered that RIP1 kinase is a key molecule that induces 
necrotic cell death mediated by death receptors [80]. 
Recently, three independent studies have identified that the 
interaction of RIP1 and RIP3 through their RHIM domain 
is a critical step for the phosphorylation of their kinase 
domains and subsequent necrosis (Fig. 3C) [81,82,83]. 
The  complex  containing  RIP1  and  RIP3  is  termed  the 
necrosome. Although RIP1 is expressed ubiquitously in 
all cell types, RIP3 expression levels differ amongst cells 
and tissue [82,84]. Interestingly, He and others showed 
that death receptor-mediated necrosis correlates with RIP3 
expression levels [82]. Gene knockout or knockdown of 
RIP3  completely  inhibits  RIP1  kinase  phosphorylation 
and subsequent necrosis after death receptor stimulation 
[81]. These findings indicate that RIP3 is a key regulator 
of RIP1 kinase phosphorylation and necrotic signaling.
In 2005, Degterev, Yuan, and others using chemical 
library  screening,  identified  small  compounds  named 
necrostatins  that  specifically  inhibit  death  receptor-
mediated necrosis [25]. Necrostatins have been shown to 
specifically inhibit RIP1 kinase phosphorylation during 
necrosis  without  affecting  death  receptor-induced  NF-
κB  activation  [85].  RIP1  kinase  activity  appears  to  be 
important for necrosome formation, as necrostatin-1 
abolishes the formation of the RIP1-RIP3 complex and 
RIP3  kinase  phosphorylation  during  necrosis  [81,82]. 
Cho  and  others  propose  that  another  unknown  kinase 
activated by RIP1 may mediate RIP3 phosphorylation, 
based on the findings that ectopically expressed RIP1 does 
not phosphorylate RIP3 [81]. The activities of RIP1 and 
RIP3 may be mutually regulated in a necrosome signaling 
complex. 
the role oF rIp KInAse In 
photoreceptor deAth
During retinal degeneration, death ligands such 
as TNF-α and Fas-L are shown to be up-regulated and 
contribute to photoreceptor death [40,86]. As described 
above, death ligands can induce not only apoptosis but 
also necrosis. In addition, previous morphological analysis 
of photoreceptor death demonstrated the presence of 
both apoptosis and necrosis in retinal degeneration [60]. 
Figure 5: rIp kinase-mediated necrosis as a redundant mechanism of photoreceptor death. Photoreceptor death is caused 
mainly by apoptosis after retinal detachment (left bar). Caspase inhibition by Z-VAD decreases apoptosis but promotes RIP kinase-mediated 
necrosis (middle bar). Blockade of both caspases and RIP kinases is required for effective prevention of photoreceptor loss (right bar).
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However, most of studies have not focused on necrosis 
since it was believed that necrosis is an unregulated 
form of cell death. In our recent work, we investigated 
the role of RIP kinase-mediated necrosis in experimental 
models  of  retinal  detachment,  and  observed  that  RIP3 
expression increases over 10-fold in the detached retina, 
especially in the outer nuclear layer. Morphological 
assessment revealed that necrotic photoreceptor death 
occurs after retinal detachment, although its frequency 
is approximately half that of apoptosis (Fig. 4A and D). 
Interestingly,  treatment  with  the  pan-caspase  inhibitor 
Z-VAD decreases apoptosis but exacerbates necrosis after 
retinal detachment (Fig. 4B and D). The necrotic changes 
after caspase inhibition are reversed by co-treatment 
with Nec-1 or by genetic knockout of RIP3 (Fig. 4C and 
D)[64].  These  data  indicate  that  RIP  kinase-mediated 
necrosis is an alternative pathway of photoreceptor 
death, which is utilized particularly when caspases are 
inhibited, and suggest that simultaneous inhibition of 
both  RIP  kinase  and  caspase  pathways  are  necessary 
for effective prevention of photoreceptor death (Fig. 5). 
Since several death ligands are up-regulated during retinal 
degeneration [40,86], targeting the common downstream, 
i.e. RIP kinases and caspases, may be a useful strategy for 
preventing photoreceptor death mediated by various death 
signals. 
One unexpected finding of our study is that RIP3 
deficiency  attenuates  apoptotic  photoreceptor  death  as 
well  as  necrosis  after  retinal  detachment.  In  contrast, 
necrostatin-1 prevents only necrotic photoreceptor death 
without  affecting  apoptosis  [64].  It  remains  unclear 
whether RIP3 signaling may affect not only RIP1 kinase-
mediated necrotic pathway but also unknown apoptotic 
pathways. Previous studies reported that over-expression 
of  RIP3  in  cells  leads  to  apoptosis  induction  [84,87]. 
Moreover, Upton and others recently demonstrated 
that  mouse  cytomegalovirus  infection  induces  RIP3-
dependent but RIP1-independent cell death in 3T3-Swiss 
albino fibroblasts [88]. These results suggest that RIP3 
kinase  may  have  additional  substrates  in  addition  to 
RIP1.  Further  biochemical and  morphological analyses 
of RIP kinase-mediated cell death and identification of 
the direct substrates of RIP1 and RIP3 will further the 
characterization of RIP signaling pathways.
downstreAm tArgets oF rIp 
KInAses
rIp and reactive oxygen species
Previous studies in the 1990s reported that 
overproduction of reactive oxygen species (ROS) occurs 
in death receptor-mediated necrosis [79,89]. Consistent 
with  these  findings,  recent  studies  have  revealed  the 
molecular links between RIP kinases and ROS-regulating 
enzymes. First, activated RIP3 interacts with metabolic 
enzymes  such  as  glycogen  phosphorylase  (PYGL), 
glutamate-ammonia  ligase  (GLUL)  and  glutamate 
dehydrogenase  1  (GLUD1)  [83].  PYGL  catalyzes  the 
degradation of glycogen to glucose-1-phosphate. GLUL 
and GLUD1 mediate glutaminolysis. GLUL catalyzes the 
synthesis of glutamine from glutamate and ammonia, and 
GLUD1 is a mitochondria matrix enzyme that converts 
glutamine to α-ketoglutarate. Activation of these enzymes 
eventually stimulates the Krebs cycle and oxidative 
phosphorylation, thereby increasing mitochondrial ROS 
production.  Secondly,  after  TNF-α  stimulation,  RIP1 
forms  a  complex  with  TNFR,  Riboflavin  kinase,  and 
NADPH oxidase 1 [90,91]. NADPH oxidase is the best-
characterized  non-mitochondrial  source  of  ROS  and 
forms a membrane bound enzyme complex with p22phox 
and Rac [92]. This complex generates superoxide by 
transferring  an  electron  from  NADPH  in  the  cytsol  to 
oxygen on the luminal side or in the extracellular space. 
Thirdly, RIP1 kinase activates autophagic degradation of 
catalase, which converts hydrogen peroxide to water and 
oxygen, thereby increasing ROS accumulation [93]. The 
requirement  of  ROS  for  RIP  kinase-mediated  necrosis 
has been demonstrated in several (albeit not all) types of 
cells [94]. In vivo, oxidative retinal damage after retinal 
detachment is suppressed by RIP kinase inhibition [64]. 
These  findings  suggest  that  ROS  overproduction  is  an 
important downstream target of the RIP kinases during 
retinal detachment-induced photoreceptor necrosis. 
Oxidative stress has been implicated as a key mediator of 
photoreceptor death in various retinal diseases including 
age-related  macular  degeneration  [95,96],  retinitis 
pigmentosa [97] as well as retinal detachment [64,98]. 
Further studies will be required to address whether RIP 
kinases affect ROS production and photoreceptor death in 
a broad range of retinal disorders.
rIp-mediated necrosis and mitochondrial 
permeability transition
The release of mitochondiral proteins into the 
cytoplasm is a key event during cell death [99]. There 
are at least two distinct mechanisms for mitochondrial 
membrane permeabilization. First, mitochondrial outer 
membrane permeabilization (MOMP) is initiated by the 
formation of the Bax channel at the outer mitochondrial 
membrane, allowing for the release of cytochrom c 
and other intermembrane space proteins. Secondly, 
mitochondrial permeability transition (MPT) results from 
the opening of the permeability transition pore complex 
(PTPC), a polyprotein complex formed at the junction 
between the inner and outer mitochondrial membrane. 
The opening of PTPC leads to loss of the mitochondrial 
membrane potential, an influx of fluid into the matrix, Oncotarget 2011; 2:  497 - 509 504 www.impactjournals.com/oncotarget
swelling and rupturing of the outer mitochondrial 
membrane, and non-selective release of pro-death 
proteins [100]. It is postulated that apoptosis and necrosis 
may preferentially involve MOMP and MPT, respectively 
[101]. 
PTPC is a polyprotein complex primarily composed 
of voltage-dependent anion chanel (VDAC) in the outer 
membrane,  adenine  nucleotide  translocator  (ANT)  in 
the inner membrane, and cyclophilin D in the matrix. 
Cyclophilin D is a critical component of PTPC formation, 
as genetic knockout of cyclophilin D prevents MPT and 
subsequent necrosis following H2O2 exposure or Ca2+ 
overload [102]. He and others recently reported that 
cyclophilin  D-deficient  MEFs  are  partially  resistant  to 
death receptor-mediated necrosis [82], suggesting that 
RIP  kinase  mediates  necrosis  through  PTPC  opening, 
at  least  in  part.  It  is  likely  that  MPT  is  important  for 
photoreceptor death, as HIV protease inhibitors, which 
prevent PTPC opening, prevent cell death after retinal 
detachment [41,103]. In another study, RIP1 kinase was 
shown to inhibit the ANT function of transporting ADP 
into the mitochondria, resulting in reduced ATP and 
necrotic cell death [104]. Further studies of the molecular 
links  between  RIP  kinase  and  PTPC  components  are 
required to elucidate the molecular signaling of necrosis.
rIp and AIF
AIF is a flavoprotein, which, in the healthy state, is 
located in the mitochondrial intermembrane space and 
exerts a vital function in energy and redox metabolism 
[105]. However, under stress conditions, AIF is cleaved, 
translocates to the nucleus, and promotes chromatinolysis 
and  cell  death.  AIF  was  first  identified  as  a  caspse-
independent inducer of apoptosis [106], and recent 
studies showed that it also mediates programmed necrosis 
[28,107].  The  translocation  of  AIF  into  the  nucleus 
has been observed during photoreceptor death after 
retinal detachment and in inherited retinal degeneration 
[4,44,108]. Reduced AIF expression in Harlequin mutant 
mice reduces photoreceptor loss after retinal detachment 
[41].  Furthermore,  our  recent  study  showed  that  RIP 
kinase inhibition prevents AIF nuclear translocation after 
retinal  detachment  [64],  suggesting  the  link  between 
RIP  kinase  and  AIF  signaling.  However,  the  precise 
molecular mechanisms by which RIP kinase regulates AIF 
translocation remain to be elucidated, as there are several 
steps between AIF translocation to cell death induction: 
processing  of  AIF  in  the  intermembrane  space  [109], 
mitochondrial membrane permeabilization [110], and 
interaction with cyclophilin A for nuclear transport and 
chromatinolysis [111,112]. 
conclusIons
Photoreceptor death in retinal degenerative disorders 
has been thought to be caused mainly by apoptosis. 
However,  despite  more  than  a  decade  of  work  on 
apoptosis, attempts to move drug-based neuroprotection 
for retinal degenerative diseases have failed [113]. Recent 
accumulating  evidence  identifies  RIP  kinase-mediated 
necrosis as an alternative pathway of cell death. In an 
experimental model of retinal detachment, we showed that, 
when caspase pathways are blocked, RIP kinase pathways 
promote photoreceptor necrosis and overcomes apoptosis 
inhibition.  These  findings  suggest  that  photoreceptor 
death is redundantly regulated by apoptosis and necrosis, 
and that combined targeting of RIP kinases and caspases 
may provide effective neuroprotection in retinal disorders 
associated with photoreceptor loss. 
AcKnowledgements. 
We would like to thank to Dr. Aristomenis Thanos 
for  providing  the  scheme  for  Fig.  1,  2,  3  and  5. This 
work was supported by Bacardi Fund (DGV), Research 
to  Prevent  Blindness  Foundation  (DGV),  Lions  Eye 
Research Fund (DGV), Onassis Foundation (DGV), Fight 
For Sight Grant in Aid (DGV), Harvard Ophthalmology 
Department  Support  (DGV)  and  NEI  grant  EY014104 
(MEEI Core Grant). 
competIng Interests stAtement.
MEEI  has  the  provisional  patent  filling.  D.G.V., 
Y.M. and J.W.M. are inventors.
reFerence
1.  Dunaief  JL,  Dentchev  T,  Ying  GS,  Milam  AH.  The  role 
of apoptosis in age-related macular degeneration. Arch 
Ophthalmol. 2002; 120: 1435-1442.
2.  Barber  AJ,  Lieth  E,  Khin  SA,  Antonetti  DA,  Buchanan 
AG, Gardner TW. Neural apoptosis in the retina during 
experimental and human diabetes. Early onset and effect of 
insulin. J Clin Invest. 1998; 102: 783-791.
3.  Cook  B,  Lewis  GP,  Fisher  SK,  Adler  R.  Apoptotic 
photoreceptor degeneration in experimental retinal 
detachment. Invest Ophthalmol Vis Sci. 1995; 36: 990-996.
4. Hisatomi T, Sakamoto T, Murata T, Yamanaka I, Oshima 
Y, Hata Y, Ishibashi T, Inomata H, Susin SA, Kroemer 
G. Relocalization of apoptosis-inducing factor in 
photoreceptor apoptosis induced by retinal detachment in 
vivo. Am J Pathol. 2001; 158: 1271-1278.
5. Zacks DN, Hanninen V, Pantcheva M, Ezra E, Grosskreutz C, 
Miller JW. Caspase activation in an experimental model of 
retinal detachment. Invest Ophthalmol Vis Sci. 2003; 44: 
1262-1267.
6.  Arroyo  JG,  Yang  L,  Bula  D,  Chen  DF.  Photoreceptor 
apoptosis in human retinal detachment. Am J Ophthalmol. Oncotarget 2011; 2:  497 - 509 505 www.impactjournals.com/oncotarget
2005; 139: 605-610.
7. Congdon N, Vingerling JR, Klein BE, West S, Friedman DS, 
Kempen J, O’Colmain B, Wu SY, Taylor HR. Prevalence 
of cataract and pseudophakia/aphakia among adults in the 
United States. Arch Ophthalmol. 2004; 122: 487-494.
8.  Jager  RD,  Mieler  WF,  Miller  JW.  Age-related  macular 
degeneration. N Engl J Med. 2008; 358: 2606-2617.
9. Gragoudas ES, Adamis AP, Cunningham ET, Jr., Feinsod M, 
Guyer DR. Pegaptanib for neovascular age-related macular 
degeneration. N Engl J Med. 2004; 351: 2805-2816.
10. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, 
Chung CY, Kim RY. Ranibizumab for neovascular age-
related macular degeneration. N Engl J Med. 2006; 355: 
1419-1431.
11. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim 
RY, Sy JP, Schneider S. Ranibizumab versus verteporfin 
for neovascular age-related macular degeneration. N Engl J 
Med. 2006; 355: 1432-1444.
12. Curcio CA, Medeiros NE, Millican CL. Photoreceptor loss 
in  age-related  macular  degeneration.  Invest  Ophthalmol 
Vis Sci. 1996; 37: 1236-1249.
13.  Sarks  JP,  Sarks  SH,  Killingsworth  MC.  Evolution  of 
geographic atrophy of the retinal pigment epithelium. Eye 
(Lond). 1988; 2: 552-577.
14. Eckardt C, Eckardt U. Macular translocation in nonexudative 
age-related macular degeneration. Retina. 2002; 22: 786-
794.
15.  Cahill  MT,  Mruthyunjaya  P,  Bowes  Rickman  C,  Toth 
CA. Recurrence of retinal pigment epithelial changes 
after  macular  translocation  with  360  degrees  peripheral 
retinectomy  for  geographic  atrophy.  Arch  Ophthalmol. 
2005; 123: 935-938.
16. Khurana RN, Fujii GY, Walsh AC, Humayun MS, de Juan E, 
Jr., Sadda SR. Rapid recurrence of geographic atrophy after 
full macular translocation for nonexudative age-related 
macular degeneration. Ophthalmology. 2005; 112: 1586-
1591.
17. Hartong DT, Berson EL, Dryja TP. Retinitis pigmentosa. 
Lancet. 2006; 368: 1795-1809.
18.  Sancho-Pelluz  J,  Arango-Gonzalez  B,  Kustermann  S, 
Romero FJ, van Veen T, Zrenner E, Ekstrom P, Paquet-
Durand F. Photoreceptor cell death mechanisms in inherited 
retinal degeneration. Mol Neurobiol. 2008; 38: 253-269.
19.  Jacobson  SG,  Cideciyan  AV.  Treatment  possibilities  for 
retinitis pigmentosa. N Engl J Med. 2010; 363: 1669-1671.
20. Kroemer G, Galluzzi L, Vandenabeele P, Abrams J, Alnemri 
ES,  Baehrecke  EH,  Blagosklonny  MV,  El-Deiry  WS, 
Golstein P, Green DR, Hengartner M, Knight RA, Kumar 
S, Lipton SA, Malorni W, Nunez G, ea al. Classification 
of  cell  death:  recommendations  of  the  Nomenclature 
Committee on Cell Death 2009. Cell Death Differ. 2009; 
16: 3-11.
21. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological 
phenomenon with wide-ranging implications in tissue 
kinetics. Br J Cancer. 1972; 26: 239-257.
22. Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation 
during apoptosis. Nat Rev Mol Cell Biol. 2004; 5: 897-907.
23. Vandenabeele P, Galluzzi L, Vanden Berghe T, Kroemer G. 
Molecular mechanisms of necroptosis: an ordered cellular 
explosion. Nat Rev Mol Cell Biol. 2010; 11: 700-714.
24. Chan FK, Shisler J, Bixby JG, Felices M, Zheng L, Appel 
M, Orenstein J, Moss B, Lenardo MJ. A role for tumor 
necrosis factor receptor-2 and receptor-interacting protein 
in  programmed  necrosis  and  antiviral  responses.  J  Biol 
Chem. 2003; 278: 51613-51621.
25. Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima 
N,  Cuny  GD,  Mitchison  TJ,  Moskowitz  MA,  Yuan 
J.  Chemical  inhibitor  of  nonapoptotic  cell  death  with 
therapeutic potential for ischemic brain injury. Nat Chem 
Biol. 2005; 1: 112-119.
26. Krysko O, De Ridder L, Cornelissen M. Phosphatidylserine 
exposure during early primary necrosis (oncosis) in JB6 
cells as evidenced by immunogold labeling technique. 
Apoptosis. 2004; 9: 495-500.
27.  Grasl-Kraupp  B,  Ruttkay-Nedecky  B,  Koudelka  H, 
Bukowska  K,  Bursch  W,  Schulte-Hermann  R.  In  situ 
detection  of  fragmented  DNA  (TUNEL  assay)  fails  to 
discriminate among apoptosis, necrosis, and autolytic cell 
death: a cautionary note. Hepatology. 1995; 21: 1465-1468.
28. Artus C, Boujrad H, Bouharrour A, Brunelle MN, Hoos S, 
Yuste VJ, Lenormand P, Rousselle JC, Namane A, England 
P, Lorenzo HK, Susin SA. AIF promotes chromatinolysis 
and caspase-independent programmed necrosis by 
interacting with histone H2AX. EMBO J. 2010; 29:1585-
1599.
29.  Schweichel  JU,  Merker  HJ.  The  morphology  of  various 
types of cell death in prenatal tissues. Teratology. 1973; 7: 
253-266.
30.  Clarke  PG.  Developmental  cell  death:  morphological 
diversity and multiple mechanisms. Anat Embryol (Berl). 
1990; 181: 195-213.
31. Bredesen DE, Rao RV, Mehlen P. Cell death in the nervous 
system. Nature. 2006; 443: 796-802.
32. Nagata S. Apoptosis by death factor. Cell. 1997; 88: 355-
365.
33. Peter ME, Krammer PH. The CD95(APO-1/Fas) DISC and 
beyond. Cell Death Differ. 2003; 10: 26-35.
34. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, 
a Bcl2 interacting protein, mediates cytochrome c release 
from mitochondria in response to activation of cell surface 
death receptors, Cell. 1998; 94: 481-490.
35. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 
mediates the mitochondrial damage in the Fas pathway of 
apoptosis. Cell. 1998; 94: 491-501.
36. Wang X. The expanding role of mitochondria in apoptosis. 
Genes Dev. 2001; 15: 2922-2933.
37. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, 
Alnemri ES, Wang X. Cytochrome c and dATP-dependent Oncotarget 2011; 2:  497 - 509 506 www.impactjournals.com/oncotarget
formation of Apaf-1/caspase-9 complex initiates an 
apoptotic protease cascade. Cell. 1997; 91: 479-489.
38. Du C, Fang M, Li Y, Li L, Wang X. Smac, a mitochondrial 
protein that promotes cytochrome c-dependent caspase 
activation by eliminating IAP inhibition. Cell. 2000; 102: 
33-42.
39. Verhagen AM, Ekert PG, Pakusch M, Silke J, Connolly LM, 
Reid GE, Moritz RL, Simpson RJ, Vaux DL. Identification 
of DIABLO, a mammalian protein that promotes apoptosis 
by binding to and antagonizing IAP proteins. Cell. 2000; 
102:43-53.
40. Zacks DN, Zheng QD, Han Y, Bakhru R, Miller JW. FAS-
mediated apoptosis and its relation to intrinsic pathway 
activation in an experimental model of retinal detachment. 
Invest Ophthalmol Vis Sci. 2004; 45: 4563-4569. 
41. Hisatomi T, Nakazawa T, Noda K, Almulki L, Miyahara S, 
Nakao S, Ito Y, She H, Kohno R, Michaud N, Ishibashi T, 
Hafezi-Moghadam A, Badley AD, Kroemer G, Miller JW. 
HIV protease inhibitors provide neuroprotection through 
inhibition of mitochondrial apoptosis in mice. J Clin Invest. 
2008; 118: 2025-2038.
42. Doonan F, Donovan M, Cotter TG. Caspase-independent 
photoreceptor apoptosis in mouse models of retinal 
degeneration. J Neurosci. 2003; 23: 5723-5731.
43. Zeiss CJ, Neal J, Johnson EA. Caspase-3 in postnatal retinal 
development and degeneration. Invest Ophthalmol Vis Sci. 
2004; 45: 964-970.
44. Sanges D, Comitato A, Tammaro R, Marigo V. Apoptosis in 
retinal degeneration involves cross-talk between apoptosis-
inducing factor (AIF) and caspase-12 and is blocked by 
calpain inhibitors. Proc Natl Acad Sci U S A 2006. 103; 
17366-17371.
45. Yoshizawa K, Kiuchi K, Nambu H, Yang J, Senzaki H, 
Kiyozuka Y, Shikata N, Tsubura A. Caspase-3 inhibitor 
transiently delays inherited retinal degeneration in 
C3H mice carrying the rd gene. Graefes Arch Clin Exp 
Ophthalmol. 2002; 240: 214-219.
46. Yakovlev AG, Ota K, Wang G, Movsesyan V, Bao WL, 
Yoshihara  K,  Faden  AI.  Differential  expression  of 
apoptotic protease-activating factor-1 and caspase-3 genes 
and susceptibility to apoptosis during brain development 
and  after  traumatic  brain  injury.  J  Neurosci.  2001;  21: 
7439-7446.
47. Donovan M, Cotter TG. Caspase-independent photoreceptor 
apoptosis in vivo and differential expression of apoptotic 
protease activating factor-1 and caspase-3 during retinal 
development. Cell Death Differ. 2002; 9: 1220-1231.
48. Wright KM, Linhoff MW, Potts PR, Deshmukh M. Decreased 
apoptosome activity with neuronal differentiation sets the 
threshold for strict IAP regulation of apoptosis. J Cell Biol. 
2004; 167: 303-313.
49.  Segura  MF,  Sole  C,  Pascual  M,  Moubarak  RS,  Perez-
Garcia MJ, Gozzelino R, Iglesias V, Badiola N, Bayascas 
JR, Llecha N, Rodriguez-Alvarez J, Soriano E, Yuste VJ, 
Comella  JX.  The  long  form  of  Fas  apoptotic  inhibitory 
molecule is expressed specifically in neurons and protects 
them against death receptor-triggered apoptosis. J Neurosci. 
2007; 27: 11228-11241.
50. Zacks DN, Han Y, Zeng Y, Swaroop A. Activation of signaling 
pathways and stress-response genes in an experimental 
model of retinal detachment. Invest Ophthalmol Vis Sci. 
2006; 47: 1691-1695.
51. Rohrer B, Pinto FR, Hulse KE, Lohr HR, Zhang L, Almeida 
JS. Multidestructive pathways triggered in photoreceptor 
cell death of the rd mouse as determined through gene 
expression profiling. J Biol Chem. 2004; 279: 41903-41910.
52. Hisatomi T, Sakamoto T, Sonoda KH, Tsutsumi C, Qiao H, 
Enaida H, Yamanaka I, Kubota T, Ishibashi T, Kura S, Susin 
SA, Kroemer G. Clearance of apoptotic photoreceptors: 
elimination of apoptotic debris into the subretinal space and 
macrophage-mediated phagocytosis via phosphatidylserine 
receptor and integrin alphavbeta3. Am J Pathol. 2003; 162: 
1869-1879.
53. Paquet-Durand F, Silva J, Talukdar T, Johnson LE, Azadi S, 
van Veen T, Ueffing M, Hauck SM, Ekstrom PA. Excessive 
activation of poly(ADP-ribose) polymerase contributes 
to inherited photoreceptor degeneration in the retinal 
degeneration 1 mouse. J Neurosci. 2007; 27: 10311-10319.
54. Fischer U, Schulze-Osthoff K. Apoptosis-based therapies 
and drug targets. Cell Death Differ. 2005; 12 Suppl 1: 942-
961.
55. Hoglen NC, Chen LS, Fisher CD, Hirakawa BP, Groessl T, 
Contreras PC. Characterization of IDN-6556 (3-[2-(2-tert-
butyl-phenylaminooxalyl)-amino]-propionylamino]-4-
oxo-5-(2,3  ,5,6-tetrafluoro-phenoxy)-pentanoic  acid):  a 
liver-targeted  caspase  inhibitor.  J  Pharmacol  Exp  Ther. 
2004; 309: 634-640.
56.  Valentino  KL,  Gutierrez  M,  Sanchez  R,  Winship  MJ, 
Shapiro DA. First clinical trial of a novel caspase inhibitor: 
anti-apoptotic caspase inhibitor, IDN-6556, improves liver 
enzymes. Int J Clin Pharmacol Ther. 2003; 41: 441-449.
57.  Shiffman  ML,  Pockros  P,  McHutchison  JG,  Schiff  ER, 
Morris M, Burgess G. Clinical trial: the efficacy and safety 
of oral PF-03491390, a pancaspase inhibitor - a randomized 
placebo-controlled study in patients with chronic hepatitis 
C. Aliment Pharmacol Ther. 2010; 31: 969-978.
58. Baskin-Bey ES, Washburn K, Feng S, Oltersdorf T, Shapiro 
D, Huyghe M, Burgart L, Garrity-Park M, van Vilsteren 
FG,  Oliver  LK,  Rosen  CB,  Gores  GJ.  Clinical  Trial  of 
the  Pan-Caspase  Inhibitor,  IDN-6556,  in  Human  Liver 
Preservation Injury. Am J Transplant. 2007; 7: 218-225.
59. Ray SK. Currently evaluated calpain and caspase inhibitors 
for neuroprotection in experimental brain ischemia. Curr 
Med Chem. 2006; 13: 3425-3440.
60. Erickson PA, Fisher SK, Anderson DH, Stern WH, Borgula 
GA. Retinal detachment in the cat: the outer nuclear and 
outer plexiform layers. Invest Ophthalmol Vis Sci. 1983; 
24: 927-942.Oncotarget 2011; 2:  497 - 509 507 www.impactjournals.com/oncotarget
61. Shahinfar S, Edward DP, Tso MO. A pathologic study of 
photoreceptor cell death in retinal photic injury. Curr Eye 
Res. 1991; 10: 47-59.
62. Arimura N, Ki-i Y, Hashiguchi T, Kawahara K, Biswas KK, 
Nakamura M, Sonoda Y, Yamakiri K, Okubo A, Sakamoto 
T, Maruyama I. Intraocular expression and release of high-
mobility group box 1 protein in retinal detachment. Lab 
Invest. 2009; 89: 278-289.
63. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin 
protein HMGB1 by necrotic cells triggers inflammation. 
Nature. 2002; 418: 191-195.
64.  Trichonas  G,  Murakami  Y,  Thanos  A,  Morizane  Y, 
Kayama  M,  Debouck  CM,  Hisatomi  T,  Miller  JW, 
Vavvas DG. Receptor interacting protein kinases mediate 
retinal detachment-induced photoreceptor necrosis and 
compensate for inhibition of apoptosis. Proc Natl Acad Sci 
U S A. 2010; 107: 21695-21700. 
65. Rosenbaum DM, Degterev A, David J, Rosenbaum PS, Roth 
S, Grotta JC, Cuny GD, Yuan J, Savitz SI. Necroptosis, a 
novel form of caspase-independent cell death, contributes 
to neuronal damage in a retinal ischemia-reperfusion injury 
model. J Neurosci Res. 2010; 88: 1569-1576.
66. Vandenabeele P, Declercq W, Van Herreweghe F, Vanden 
Berghe T. The role of the kinases RIP1 and RIP3 in TNF-
induced necrosis. Sci Signal. 2010; 3: re4.
67. Micheau O, Tschopp J. Induction of TNF receptor I-mediated 
apoptosis via two sequential signaling complexes. Cell. 
2003; 114: 181-190.
68. Mahoney DJ, Cheung HH, Mrad RL, Plenchette S, Simard 
C, Enwere E, Arora V, Mak TW, Lacasse EC, Waring J, 
Korneluk RG. Both cIAP1 and cIAP2 regulate TNFalpha-
mediated NF-kappaB activation. Proc Natl Acad Sci U S A. 
2008; 105: 11778-11783.
69. Ea CK, Deng L, Xia ZP, Pineda G, Chen ZJ. Activation of 
IKK by TNFalpha requires site-specific ubiquitination of 
RIP1 and polyubiquitin binding by NEMO. Mol Cell. 2006; 
22: 245-257.
70. Varfolomeev E, Goncharov T, Fedorova AV, Dynek JN, 
Zobel K, Deshayes K, Fairbrother WJ, Vucic D. c-IAP1 
and c-IAP2 are critical mediators of tumor necrosis factor 
alpha  (TNFalpha)-induced  NF-kappaB  activation.  J  Biol 
Chem. 2008; 283: 24295-24299.
71. Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ, Leder 
P. The death domain kinase RIP mediates the TNF-induced 
NF-kappaB signal. Immunity. 1998; 8: 297-303.
72. Shembade N, Ma A, Harhaj EW. Inhibition of NF-kappaB 
signaling by A20 through disruption of ubiquitin enzyme 
complexes. Science. 2010; 327: 1135-1139.
73. Wright A, Reiley WW, Chang M, Jin W, Lee AJ, Zhang M, 
Sun SC. Regulation of early wave of germ cell apoptosis 
and spermatogenesis by deubiquitinating enzyme CYLD. 
Dev Cell. 2007; 13: 705-716.
74. Stanger BZ, Leder P, Lee TH, Kim E, Seed B. RIP: a novel 
protein containing a death domain that interacts with Fas/
APO-1 (CD95) in yeast and causes cell death. Cell. 1995; 
81: 513-523.
75. Muppidi JR, Lobito AA, Ramaswamy M, Yang JK, Wang L, 
Wu H, Siegel RM. Homotypic FADD interactions through 
a conserved RXDLL motif are required for death receptor-
induced apoptosis. Cell. Death Differ. 2006; 13: 1641-1650.
76. Morgan MJ, Kim YS, Liu ZG. Membrane-bound Fas ligand 
requires RIP1 for efficient activation of caspase-8 within 
the death-inducing signaling complex. J Immunol. 2009; 
183: 3278-3284.
77. Lin Y, Devin A, Rodriguez Y, Liu ZG. Cleavage of the death 
domain  kinase  RIP  by  caspase-8  prompts  TNF-induced 
apoptosis. Genes Dev. 1999; 13: 2514-2526.
78. Vercammen D, Beyaert R, Denecker G, Goossens V, Van 
Loo G, Declercq W, Grooten J, Fiers W, Vandenabeele P. 
Inhibition of caspases increases the sensitivity of L929 cells 
to necrosis mediated by tumor necrosis factor. J Exp Med. 
1998; 187: 1477-1485.
79. Vercammen D, Brouckaert G, Denecker G, Van de Craen 
M, Declercq W, Fiers W, Vandenabeele P. Dual signaling 
of the Fas receptor: initiation of both apoptotic and necrotic 
cell death pathways. J Exp Med. 1998; 188: 919-930.
80. Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti 
S, Bodmer JL, Schneider P, Seed B, Tschopp J. Fas triggers 
an alternative, caspase-8-independent cell death pathway 
using the kinase RIP as effector molecule. Nat Immunol. 
2000; 1: 489-495.
81. Cho YS, Challa S, Moquin D, Genga R, Ray TD, Guildford 
M, Chan FK. Phosphorylation-driven assembly of the 
RIP1-RIP3  complex  regulates  programmed  necrosis  and 
virus-induced inflammation. Cell. 2009; 137: 1112-1123.
82. He S, Wang L, Miao L, Wang T, Du F, Zhao L, Wang X. 
Receptor interacting protein kinase-3 determines cellular 
necrotic  response  to  TNF-alpha.  Cell.  2009;  137:  1100-
1111.
83. Zhang DW, Shao J, Lin J, Zhang N, Lu BJ, Lin SC, Dong 
MQ,  Han  J.  RIP3,  an  energy  metabolism  regulator  that 
switches  TNF-induced  cell  death  from  apoptosis  to 
necrosis. Science. 2009; 325: 332-336.
84. Sun X, Lee J, Navas T, Baldwin DT, Stewart TA, Dixit VM. 
RIP3,  a  novel  apoptosis-inducing  kinase.  J  Biol  Chem. 
1999; 274: 16871-16875.
85. Degterev A, Hitomi J, Germscheid M, Ch’en IL, Korkina O, 
Teng X, Abbott D, Cuny GD, Yuan C, Wagner G, Hedrick 
SM, Gerber SA, Lugovskoy A, Yuan J. Identification of 
RIP1 kinase as a specific cellular target of necrostatins. Nat 
Chem Biol. 2008; 4: 313-321.
86. Nakazawa T, Matsubara A, Noda K, Hisatomi T, She H, 
Skondra  D,  Miyahara  S,  Sobrin  L,  Thomas  KL,  Chen 
DF,  Grosskreutz  CL,  Hafezi-Moghadam  A,  Miller 
JW.  Characterization  of  cytokine  responses  to  retinal 
detachment in rats. Mol Vis. 2006; 12: 867-878.
87. Yang Y, Ma J, Chen Y, Wu M. Nucleocytoplasmic shuttling 
of receptor-interacting protein 3 (RIP3): identification of Oncotarget 2011; 2:  497 - 509 508 www.impactjournals.com/oncotarget
novel nuclear export and import signals in RIP3. J Biol 
Chem. 2004; 279: 38820-38829.
88. Upton JW, Kaiser WJ, Mocarski ES. Virus inhibition of 
RIP3-dependent necrosis. Cell Host Microbe. 2010; 7: 302-
313.
89. Goossens V, Grooten J, De Vos K, Fiers W. Direct evidence 
for tumor necrosis factor-induced mitochondrial reactive 
oxygen intermediates and their involvement in cytotoxicity. 
Proc Natl Acad Sci U S A. 1995; 92: 8115-8119.
90.  Kim  YS,  Morgan  MJ,  Choksi  S,  Liu  ZG.  TNF-induced 
activation of the Nox1 NADPH oxidase and its role in the 
induction of necrotic cell death. Mol Cell. 2007; 26: 675-
687.
91. Yazdanpanah B, Wiegmann K, Tchikov V, Krut O, Pongratz 
C, Schramm M, Kleinridders A, Wunderlich T, Kashkar 
H,  Utermohlen  O,  Bruning  JC,  Schutze  S,  Kronke  M. 
Riboflavin  kinase  couples  TNF  receptor  1  to  NADPH 
oxidase. Nature. 2009; 460: 1159-1163.
92. Sumimoto H. Structure, regulation and evolution of Nox-
family  NADPH  oxidases  that  produce  reactive  oxygen 
species. FEBS J. 2008; 275: 3249-3277.
93. Yu L, Wan F, Dutta S, Welsh S, Liu Z, Freundt E, Baehrecke 
EH,  Lenardo  M.  Autophagic  programmed  cell  death  by 
selective catalase degradation. Proc Natl Acad Sci U S A. 
2006; 103: 4952-4957.
94. Vanlangenakker N, Vanden Berghe T, Bogaert P, Laukens 
B, Zobel K, Deshayes K, Vucic D, Fulda S, Vandenabeele 
P, Bertrand MJ. cIAP1 and TAK1 protect cells from TNF-
induced  necrosis  by  preventing  RIP1/RIP3-dependent 
reactive oxygen species production. Cell Death Differ. 
2010. 
95. Hollyfield JG, Bonilha VL, Rayborn ME, Yang X, Shadrach 
KG, Lu L, Ufret RL, Salomon RG, Perez VL. Oxidative 
damage-induced inflammation initiates age-related macular 
degeneration. Nature medicine. 2008; 14: 194-198.
96. Imamura Y, Noda S, Hashizume K, Shinoda K, Yamaguchi 
M, Uchiyama S, Shimizu T, Mizushima Y, Shirasawa T, 
Tsubota K. Drusen, choroidal neovascularization, and 
retinal pigment epithelium dysfunction in SOD1-deficient 
mice: a model of age-related macular degeneration. Proc 
Natl Acad Sci U S A. 2006; 103: 11282-11287.
97.  Komeima  K,  Rogers  BS,  Lu  L,  Campochiaro  PA. 
Antioxidants reduce cone cell death in a model of retinitis 
pigmentosa. Proc Natl Acad Sci U S A. 2006; 103: 11300-
11305.
98. Roh M, Murakami Y, Thanos A, Vavvas D, Miller JW. 
Edaravone,  a  ROS  scavenger,  ameliorates  photoreceptor 
cell  death  after  experimental  retinal  detachment.  Invest 
Ophthalmol Vis Sci. 2011 (in press). 
99.  Hisatomi  T,  Ishibashi  T,  Miller  JW,  Kroemer  G. 
Pharmacological inhibition of mitochondrial membrane 
permeabilization for neuroprotection. Exp Neurol. 2009; 
218: 347-352.
100. Donovan M, Cotter TG. Control of mitochondrial integrity 
by Bcl-2 family members and caspase-independent cell 
death. Biochim Biophys Acta. 2004; 1644: 133-147.
101 Galluzzi L, Kroemer G. Necroptosis: a specialized pathway 
of programmed necrosis. Cell. 2008; 135: 1161-1163.
102.  Nakagawa  T,  Shimizu  S,  Watanabe  T,  Yamaguchi  O, 
Otsu K, Yamagata H, Inohara H, Kubo T, Tsujimoto Y. 
Cyclophilin D-dependent mitochondrial permeability 
transition regulates some necrotic but not apoptotic cell 
death. Nature; 2005; 434: 652-658.
103. Weaver JG, Tarze A, Moffat TC, Lebras M, Deniaud A, 
Brenner C, Bren GD, Morin MY, Phenix BN, Dong L, 
Jiang SX, Sim VL, Zurakowski B, Lallier J, Hardin H et al. 
Inhibition of adenine nucleotide translocator pore function 
and protection against apoptosis in vivo by an HIV protease 
inhibitor. J Clin Invest. 2005; 115: 1828-1838.
104. Temkin V, Huang Q, Liu H, Osada H, Pope RM. Inhibition 
of ADP/ATP exchange in receptor-interacting protein-
mediated necrosis. Mol Cell Biol. 2006; 26: 2215-2225.
105.  Modjtahedi  N,  Giordanetto  F,  Madeo  F,  Kroemer  G. 
Apoptosis-inducing factor: vital and lethal. Trends Cell 
Biol. 2006; 16: 264-272.
106. Susin SA, Lorenzo HK, Zamzami N, Marzo I, Snow BE, 
Brothers GM, Mangion J, Jacotot E, Costantini P, Loeffler 
M, Larochette N, Goodlett DR, Aebersold R, Siderovski 
DP, Penninger JM, Kroemer G. Molecular characterization 
of mitochondrial apoptosis-inducing factor. Nature. 1999; 
397: 441-446.
107. Moubarak RS, Yuste VJ, Artus C, Bouharrour A, Greer 
PA,  Menissier-de  Murcia  J,  Susin  SA.  Sequential 
activation of poly(ADP-ribose) polymerase 1, calpains, 
and Bax is essential in apoptosis-inducing factor-mediated 
programmed necrosis. Mol Cell Biol. 2007; 27: 4844-4862.
108. Murakami Y, Ikeda Y, Yonemitsu Y, Onimaru M, Nakagawa 
K,  Kohno  R,  Miyazaki  M,  Hisatomi  T,  Nakamura  M, 
Yabe T, Hasegawa M, Ishibashi T, Sueishi K. Inhibition 
of nuclear translocation of apoptosis-inducing factor is 
an essential mechanism of the neuroprotective activity of 
pigment epithelium-derived factor in a rat model of retinal 
degeneration. Am J Pathol. 2008; 173: 1326-1338.
109.  Polster  BM,  Basanez  G,  Etxebarria  A,  Hardwick  JM, 
Nicholls DG. Calpain I induces cleavage and release of 
apoptosis-inducing  factor  from  isolated  mitochondria.  J 
Biol Chem. 2005; 280: 6447-6454.
110. Otera H, Ohsakaya S, Nagaura Z, Ishihara N, Mihara K. 
Export of mitochondrial AIF in response to proapoptotic 
stimuli depends on processing at the intermembrane space. 
EMBO J. 2005; 24: 1375-1386.
111. Cande C, Vahsen N, Kouranti I, Schmitt E, Daugas E, 
Spahr C, Luban J, Kroemer RT, Giordanetto F, Garrido C, 
Penninger JM, Kroemer G. AIF and cyclophilin A cooperate 
in apoptosis-associated chromatinolysis. Oncogene. 2004; 
23: 1514-1521.
112. Zhu C, Wang X, Deinum J, Huang Z, Gao J, Modjtahedi 
N, Neagu MR, Nilsson M, Eriksson PS, Hagberg H, Luban Oncotarget 2011; 2:  497 - 509 509 www.impactjournals.com/oncotarget
J, Kroemer G, Blomgren K. Cyclophilin A participates in 
the nuclear translocation of apoptosis-inducing factor in 
neurons after cerebral hypoxia-ischemia. J Exp Med. 2007; 
204: 1741-1748.
113.  Danesh-Meyer  HV,  Levin  LA.  Neuroprotection: 
extrapolating from neurologic diseases to the eye. Am J 
Ophthalmol. 2009; 148: 186-191 e182.